GlassScriptPhysician profile
Gaurav Mandal
NPI 1770103459
$2,173.22
in general payments reported to CMS, 2019-2025
18 companies · $946 in 2025
The $946 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.30 · 2023: $391 · 2024: $820 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,128 · Education: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,128.14 |
| Education | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $677.71 | 2021-2025 | Tepezza, Evenity, Prolia |
| Lilly USA, LLC | $306.82 | 2024-2025 | Zepbound, Jardiance |
| Kyowa Kirin, INC. | $267.68 | 2024-2025 | Crysvita |
| Novo Nordisk INC | $203.96 | 2023-2025 | Sogroya, Wegovy, Ozempic |
| Corcept Therapeutics | $179.07 | 2024-2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $121.86 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $117.06 | 2024 | Strensiq |
| Xeris Pharmaceuticals, INC. | $44.08 | 2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $42.92 | 2025 | Omnipod |
| Abbvie INC. | $40.22 | 2024 | |
| Merck Sharp & Dohme LLC | $30.98 | 2023 | Verquvo |
| Beta Bionics, INC. | $28.91 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sanofi-Aventis U.S. LLC | $22.03 | 2025 | |
| Amneal Pharmaceuticals LLC | $21.72 | 2025 | Unithroid |
| Recordati_rare_diseases_inc. | $21.00 | 2023 | Isturisa, Signifor Lar |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $17.68 | 2025 | Tryngolza |
| Chiesi USA, INC. | $15.05 | 2025 | Mycapssa |
| Shield Therapeutics INC | $14.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaurav Mandal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.